CMMB - Chemomab Therapeutics Ltd.

1.659
-0.031   -1.869%

Share volume: 28,502
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$1.69
-0.03
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.66%
1 Month
-1.25%
3 Months
-2.98%
6 Months
-46.31%
1 Year
41.79%
2 Year
151.40%
Key data
Stock price
$1.66
P/E Ratio 
0.00
DAY RANGE
$1.65 - $1.73
EPS 
$0.04
52 WEEK RANGE
$0.83 - $3.86
52 WEEK CHANGE
$38.25
MARKET CAP 
1.127 M
YIELD 
N/A
SHARES OUTSTANDING 
14.219 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$31,502
AVERAGE 30 VOLUME 
$39,322
Company detail
CEO: Dale R. Pfost
Region: US
Website: chemomab.com
Employees: 20
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Chemomab Therapeutics Ltd. discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24.

Recent news